Menu Search
Equities

HYTN Innovations Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
85W0:FRA

HYTN Innovations Inc

Actions
  • Price (EUR)0.155
  • Today's Change0.005 / 3.33%
  • Shares traded8.83k
  • 1 Year change-24.76%
  • Beta4.2037
Data delayed at least 15 minutes, as of Feb 16 2026 13:30 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

HYTN Innovations Inc. is a Canada-based pharmaceutical company. The Company is specialized in the formulation, manufacturing, marketing, and sale of products containing psychoactive and psychotropic compounds, including cannabis-derived cannabinoids and psilocybe-derived tryptamines. It is engaged in the development of the sparkling tetrahydrocannabinol and the cannabidiol beverage business. Its product and services include GMP Cannabis Processing, GMP Psilocybin Mushroom Manufacturing, GMP Active Pharmaceutical Ingredient (API) Fabrication, Cannabis Consumer Packaged Goods, and Elevation Technology. The Company enables global market access for non-sterile pharmaceuticals. It has a manufacturing facility based in Kelowna, British Columbia. The Company’s subsidiaries include HYTN Innovations Inc., HYTN Beverage Corp, HYTN Cannabis Inc., 1306562 B.C. Ltd., and Prism Scientific Labs Inc.

  • Revenue in CAD (TTM)1.67m
  • Net income in CAD-1.52m
  • Incorporated2015
  • Employees--
  • Location
    HYTN Innovations IncUnit 303 - 890 Clement AveKELOWNA V1Y 7E4CanadaCAN
  • Phone+1 (604) 689-2454
  • Fax+1 (604) 689-2435
  • Websitehttps://www.hytn.life/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.